CURE

ELCC 2026 Highlights Real Patient Impact in Lung Cancer Care

New ELCC 2026 data show longer survival, better brain metastases control and more personalized treatment options for patients ...
CURE

8 Patients With NSCLC Survive 2 Plus Years on Ateganosine Combo

Eight patients with NSCLC treated with ateganosine plus Libtayo had over 2-year survival after prior therapies, based on ...

MAIA Biotechnology Reports Overall Survival Exceeding Two Years for Eight Patients in Ongoing Phase 2 Clinical Trial in Non-Small Cell Lung Cancer

Potential breakthrough therapeutic targets $50B+ global immunotherapy market1CHICAGO, March 31, 2026 (GLOBE NEWSWIRE) -- MAIA Biotechnology, ...
Medscape

Morning Immunotherapy Does Not Boost Lung Cancer Survival

Some studies have suggested that morning is the optimal time for immunotherapy, but a new analysis of patients with lung ...

Ivonescimab Shows Quality of Life Benefits in Chemotherapy-Free First-Line NSCLC: Health-Related Quality of Life Data from the HARMONi-2 Study Presented at ELCC 2026

Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced the results of health-related quality of life (HRQoL) data (Poster: 107P) from the HARMONi-2 study at the 2026 European Lung Cancer Congress ...
newscase

BioNTech’s Oncology Ambitions Bolstered by Promising Lung Cancer Trial Data

BioNTech SE has taken another significant step in its strategic evolution from a vaccine-focused biotech to a diversified oncology leader. Recent clinical trial ...